2 completed, 1 recruiting, 1 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Reinfection: new trials by email Literature Review of Reinfection trials Research Report on Reinfection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients EXL01, Placebo - Clostridioides Difficile Infection, Recurrent Infection | Phase 1 / Phase 2 | Recruiting | Hospices Civils de Lyon | 56 | 2024-05-07 | 2026-10-20 |
| Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Ceftriaxone 1000mg + doxycycline 100 mg, Cefixime 800mg + doxycycline 100 mg - Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection | Phase 2 | Completed | Haiphong University of Medicine and Pharmacy | 125 | 2021-07-15 | 2022-03-17 |
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
| Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence H56:IC31, Placebo - Tuberculosis, Pulmonary | Phase 2 | Completed | International AIDS Vaccine Initiative | 831 | 2019-01-31 | 2026-02-24 |
Aspergillosis (1) · Clostridium Infections (1) · Cystic Fibrosis (1) · Gonorrhea (1) · Recurrence (1) · Tuberculosis (1) · Tuberculosis, Pulmonary (1)
Bacterial Infections and Mycoses (4) · Disease Attributes (4) · Infections (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bacterial Infections (3) · Recurrence (3) · Gram-Positive Bacterial Infections (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Actinomycetales Infections (1) · Communicable Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1)
Cefixime (1) · Ceftriaxone (1) · Doxycycline (1) · Suspensions (1) · posaconazole (1)
Bambino Gesù Hospital and Research Institute (1) · Haiphong University of Medicine and Pharmacy (1) · Hospices Civils de Lyon (1) · International AIDS Vaccine Initiative (1)
France (2) · Czechia (1) · Germany (1) · Greece (1) · Ireland (1) · Italy (1) · Netherlands (1) · Portugal (1) · South Africa (1) · Spain (1) · Switzerland (1) · Tanzania (1) · United Kingdom (1) · Vietnam (1)
Adilia Warris, Prof (1) · Marissa Russell (1) · Phuong Nguyen, PhD (1)
PMID 35810277, PMID 40056922, PMID 42482138, PMID 42753987
2019 (1), 2023 (1)